Diapin Therapeutics

Diapin Therapeutics is a private, clinical-stage biotech leveraging licensed and internally developed technologies to address significant unmet needs in cardiovascular and metabolic diseases. Its lead assets are DT109, a compound showing promise in MASH and atherosclerosis, and DT678, an orally available prodrug designed to overcome limitations of the blockbuster antiplatelet drug clopidogrel. The company is strategically positioned with commercial rights retained for most global territories and has established key academic and industry collaborations to advance its programs.

Small molecule prodrug design and development targeting metabolic pathways and antiplatelet therapy.

In MASH, Diapin's DT109 faces competition from numerous late-stage programs from companies like Madrigal, 89bio, and Akero. In antiplatelets, DT678 must differentiate itself from generic clopidogrel, newer agents like ticagrelor, and potential next-generation therapies. Success will require clear clinical superiority in specific patient segments.